APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 793, Issue , 2015, Pages 19-29

  Montaldi, Ana P ^a   Godoy, Paulo R D V ^a   Sakamoto Hojo, Elza T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

APE1 gene; Base excision repair; Glioblastoma; SiRNA methodology; Temozolomide

Indexed keywords

APURINIC APYRIMIDINIC ENDONUCLEASE 1; HISTONE H2AX; PROTEIN; REDOX EFFECTOR FACTOR 1; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; ALKYLATING AGENT; APEX1 PROTEIN, HUMAN; DACARBAZINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; EXCISION REPAIR; GENE EXPRESSION; GENE SILENCING; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; DNA REPAIR; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; GLIOBLASTOMA; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; RNA, SMALL INTERFERING;

EID: 84945451228     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2015.06.001     Document Type: Article

References (65)

1. Mrugala M.M. Advances and challenges in the treatment of glioblastoma: a clinician's perspective. Discov. Med. 2013, 15:221-230.
2. Ohka F., Natsume A., Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol. Res. Int. 2012, 2012:878425.
3. Stupp R., Pica A., Mirimanoff R.O., Michielin O. A practical guide for the management of gliomas. Bull. Cancer 2007, 94:817-822.
4. Yoshimoto K., Mizoguchi M., Hata N., Murata H., Hatae R., Amano T., Nakamizo A., Sasaki T. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front. Oncol. 2012, 2:186.
5. Silber J.R., Bobola M.S., Blank A., Chamberlain M.C. O(6)-Methylguanine-DNA methyltransferase in glioma therapy: promise and problems O(6)-Methylguanine-DNA methyltransferase in glioma therapy: promise and problems. Biochim. Biophys. Acta 2012, 1826:71-82.
6. Zhang J., Stevens M.F., Bradshaw T.D. Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 2012, 5:102-114.
7. Sobol R.W., Wilson S.H. Mammalian DNA beta-polymerase in base excision repair of alkylation damage. Prog. Nucleic Acid Res. 2001, 68:57-74.
8. Tentori L., Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr. Med. Chem. 2009, 16:245-257.
9. Dhandapani K.M., Mahesh V.B., Brann D.W. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J. Neurochem. 2007, 102:522-538.
10. Carminati P.O., Donaires F.S., Marques M.M., Donadi E.A., Passos G.A., Sakamoto-Hojo E.T. Cisplatin associated with LY294002 increases cytotoxicity and induces changes in transcript profiles of glioblastoma cells. Mol. Biol. Rep. 2014, 41:165-177.
11. Atkins R.J., Ng W., Stylli S.S., Hovens C.M., Kaye A.H. Repair mechanisms help glioblastoma resist treatment. J. Clin. Neurosci. 2015, 22:14-20.
12. Abbotts R., Madhusudan S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 2010, 36:425-435.
13. Luo M., He H., Kelley M.R., Georgiadis M.M. Redox regulation of DNA repair: implications for human health and cancer therapeutic development. Antioxid. Redox Signal. 2010, 12:1247-1269.
14. Kelley M.R., Georgiadis M.M., Fishel M.L. APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1. Curr. Mol. Pharmacol. 2012, 5:36-53.
15. Bobola M.S., Blank A., Berger M.S., Stevens B.A., Silber J.R. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin. Cancer Res. 2001, 7:3510-3518.
16. Kelley M.R., Cheng L., Foster R., Tritt R., Jiang J., Broshears J., Koch M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin. Cancer Res. 2001, 7:824-830.
17. Robertson K.A., Bullock H.A., Xu Y., Tritt R., Zimmerman E., Ulbright T.M., Foster R.S., Einhorn L.H., Kelley M.R. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 2001, 61:2220-2225.
18. Wang D., Xiang D.B., Yang X.Q., Chen L.S., Li M.X., Zhong Z.Y., Zhang Y.S. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66:298-304.
19. Chen S., Xiong G., Wu S., Mo J. Downregulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 enhances the sensitivity of human pancreatic cancer cells to radiotherapy in vitro. Cancer Biother. Radiopharm. 2013, 28:169-176.
20. Xiong G.S., Sun H.L., Wu S.M., Mo J.Z. Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro. J. Dig. Dis. 2010, 11:224-230.
21. Gu X., Cun Y., Li M., Qing Y., Jin F., Zhong Z., Dai N., Qian C., Sui J., Wang D. Human apurinic/apyrimidinic endonuclease siRNA inhibits the angiogenesis induced by X-ray irradiation in lung cancer cells. Int. J. Med. Sci. 2013, 10:870-882.
22. Fishel M.L., He Y., Smith M.L., Kelley M.R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res. 2007, 13:260-267.
23. Montaldi A.P., Sakamoto-Hojo E.T. Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide. Clin. Exp. Med. 2013, 13:279-288.
24. Kaur G., Cholia R.P., Mantha A.K., Kumar R. DNA repair and redox activities and inhibitors of apurinic/apyrimidinic endonuclease 1/redox effector factor 1 (APE1/Ref-1): a comparative analysis and their scope and limitations toward anticancer drug development. J. Med. Chem. 2014, 57:10241-10256.
25. Zou G.M., Maitra A. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration. Mol. Cancer Ther. 2008, 7:2012-2021.
26. Fishel M.L., Jiang Y., Rajeshkumar N.V., Scandura G., Sinn A.L., He Y., Shen C., Jones D.R., Pollok K.E., Ivan M., Maitra A., Kelley M.R. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol. Cancer Ther. 2011, 10:1698-1708.
27. Fishel M.L., Kelley M.R. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. 2007, 28:375-395.
28. Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.C., Van Meir E.G. Frequent co-alterations of TP53 p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999, 9:469-479.
29. Hermisson M., Klumpp A., Wick W., Wischhusen J., Nagel G., Roos W., Kaina B., Weller M. O6-Methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells O6-Methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem. 2006, 96:766-776.
30. Franken N.A., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006, 1:2315-2319.
31. Tafani M., Pucci B., Russo A., Schito L., Pellegrini L., Perrone G.A., Villanova L., Salvatori L., Ravenna L., Petrangeli E., Russo M.A. Modulators of HIF1α and NFkB in cancer treatment: is it a rational approach for controlling malignant progression?. Front. Pharmacol. 2013, 4.
32. Demple B., Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu. Rev. Biochem. 1994, 63:915-948.
33. Evans A.R., Limp-Foster M., Kelley M.R. Going APE over ref-1. Mutat. Res. 2000, 461:83-108.
34. Tell G., Fantini D., Quadrifoglio F. Understanding different functions of mammalian AP endonuclease (APE1) as a promising tool for cancer treatment. Cell Mol. Life Sci. 2010, 67:3589-3608.
35. Johannessen T.C., Bjerkvig R., Tysnes B.B. DNA repair and cancer stem-like cells - potential partners in glioma drug resistance?. Cancer Treat. Rev. 2008, 34:558-567.
36. Parkinson J.F., Wheeler H.T., McDonald K.L. Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma. J. Clin. Neurosci. 2008, 15:1-8.
37. McNeill D.R., Lam W., DeWeese T.L., Cheng Y.C., Wilson D.M., 3rd Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol. Cancer Res. 2009, 7:897-906.
38. Illuzzi J.L., Wilson D.M., 3rd Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms. Curr. Med. Chem. 2012, 19:3922-3936.
39. Wang D., Luo M., Kelley M.R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 2004, 3:679-686.
40. Fung H., Demple B. Distinct roles of Ape1 protein in the repair of DNA damage induced by ionizing radiation or bleomycin. J. Biol. Chem. 2011, 286:4968-4977.
41. Cun Y., Dai N., Xiong C., Li M., Sui J., Qian C., Li Z., Wang D. Silencing of APE1 enhances sensitivity of human hepatocellular carcinoma cells to radiotherapy in vitro and in a xenograft model. PLoS One 2013, 8:e55313.
42. Fung H., Demple B. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol. Cell. 2005, 17:463-470.
43. Fishel M.L., He Y., Reed A.M., Chin-Sinex H., Hutchins G.D., Mendonca M.S., Kelley M.R. Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth. DNA Repair (Amst.) 2008, 7:177-186.
44. Loeb L.A., Preston B.D. Mutagenesis by apurinic/apyrimidinic sites. Annu. Rev. Genet. 1986, 20:201-230.
45. Yuan F., Zhang Y., Rajpal D.K., Wu X., Guo D., Wang M., Taylor J.S., Wang Z. Specificity of DNA lesion bypass by the yeast DNA polymerase eta. J. Biol. Chem. 2000, 275:8233-8239.
46. Sutton M.D., Walker G.C. Managing DNA polymerases: coordinating DNA replication, DNA repair, and DNA recombination. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8342-8349.
47. Iyer P., Srinivasan A., Singh S.K., Mascara G.P., Zayitova S., Sidone B., Fouquerel E., Svilar D., Sobol R.W., Bobola M.S., Silber J.R., Gold B. Synthesis and characterization of DNA minor groove binding alkylating agents. Chem. Res. Toxicol. 2013, 26:156-168.
48. Godoy P.R., Mello S.S., Magalhaes D.A., Donaires F.S., Nicolucci P., Donadi E.A., Passos G.A., Sakamoto-Hojo E.T. Ionizing radiation-induced gene expression changes in TP53 proficient and deficient glioblastoma cell lines. Mutat. Res. 2013, 756:46-55.
49. Zaky A., Busso C., Izumi T., Chattopadhyay R., Bassiouny A., Mitra S., Bhakat K.K. Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage. Nucleic Acids Res. 2008, 36:1555-1566.
50. Bhakat K.K., Mantha A.K., Mitra S. Transcriptional regulatory functions of mammalian AP-endonuclease (APE1/Ref-1), an essential multifunctional protein. Antioxid. Redox Signal. 2009, 11:621-638.
51. Harris L.C., Remack J.S., Houghton P.J., Brent T.P. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res. 1996, 56:2029-2032.
52. Grombacher T., Eichhorn U., Kaina B. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 1998, 17:845-851.
53. Srivenugopal K.S., Shou J., Mullapudi S.R.S., Lang F.F., Rao J.S., Ali-Osman F. Enforced expression of wild-type p53 curtails the transcription of the O-6-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin. Cancer Res. 2001, 7:1398-1409.
54. Ewald B., Sampath D., Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol. Cancer Ther. 2007, 6:1239-1248.
55. Fung H., Bennett R.A., Demple B. Key role of a downstream specificity protein 1 site in cell cycle-regulated transcription of the AP endonuclease gene APE1/APEX in NIH3T3 cells. J. Biol. Chem. 2001, 276:42011-42017.
56. Cook P.J., Ju B.G., Telese F., Wang X., Glass C.K., Rosenfeld M.G. Tyrosine dephosphorylation of H2AX modulates apoptosis in survival desicisions. Nature 2009, 458:591-597.
57. Lu X.Y., Cao K., Li Q.Y., Yuan Z.C., Lu P.S. The Synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251Cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels. J. Int. Med. Res. 2012, 40:995-1004.
58. Fisher T., Galanti G., Lavie G., Jacob-Hirsch J., Kventsel I., Zeligson S., Winkler R., Simon A.J., Amariglio N., Rechavi G., Toren A. Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. Cancer J. 2007, 13:335-344.
59. Chahal M., Abdulkarim B., Xu Y.X., Guiot M.C., Easaw J.C., Stifani N., Sabri S. O(6)-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme O(6)-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme. Mol. Cancer Ther. 2012, 11:2440-2450.
60. Yamini B., Yu X., Dolan M.E., Wu M.H., Kufe D.W., Weichselbaum R.R. Inhibition of Nuclear Factor-B activity by temozolomide involves O6-methylguanine induced inhibition of p65 dna binding. Cancer Res. 2007, 67:6889-6898.
61. Schmitt A.M., Crawley C.D., Kang S., Raleigh D.R., Yu X., Wahlstrom J.S., Voce D.J., Darga T.E., Weichselbaum R.R., Yamini B. p50 (NF-kappaB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol. Cell 2011, 44:785-796.
62. Shimizu N., Sugimoto K., Tang J., Nishi T., Sato I., Hiramoto M., Aizawa S., Hatakeyama M., Ohba R., Hatori H., Yoshikawa T., Suzuki F., Oomori A., Tanaka H., Kawaguchi H., Watanabe H., Handa H. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 2000, 18:877-881.
63. Nishi T., Shimizu N., Hiramoto M., Sato I., Yamaguchi Y., Hasegawa M., Aizawa S., Tanaka H., Kataoka K., Watanabe H., Handa H. Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J. Biol. Chem. 2002, 277:44548-44556.
64. Li J., Liu H., Xing B., Yu Y., Wang H., Chen G., Gu B., Zhang G., Wei D., Gu P., Li M., Hu W. t-AUCB an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-kappaB-p65. J. Neurooncol. 2012, 108:385-393.
65. Ando K., Hirao S., Kabe Y., Ogura Y., Sato I., Yamaguchi Y., Wada T., Handa H. A new APE1/Ref-1-dependent pathway leading to reduction of NF- B and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 2008, 36:4327-4336.